Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2024 | $64.00 | Hold | Jefferies |
| 2/1/2024 | $61.00 → $79.00 | Buy | B. Riley Securities |
| 7/19/2023 | Mkt Perform | Raymond James | |
| 5/10/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 2/9/2023 | $65.00 → $60.00 | Overweight → Equal-Weight | Stephens |
| 1/3/2023 | $60.00 → $62.00 | Outperform → In-line | Evercore ISI |
| 3/31/2022 | $106.00 | Buy | B. Riley Securities |
| 3/21/2022 | $100.00 | Outperform | Evercore ISI |
SC 13D/A - Azenta, Inc. (0000933974) (Subject)
SC 13G - Azenta, Inc. (0000933974) (Subject)
SC 13G/A - Azenta, Inc. (0000933974) (Subject)
BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 13, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solu
BURLINGTON, Mass., Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 173 $ 159 $ 166 9 % 4 % Organic growth 5 % Sample Management Solutions $ 81 $ 74 $ 75 9 % 7 % Multiomics $ 64 $ 62 $ 64 2 % (0) % B Medical Systems $ 29 $ 23 $ 27 25 % 7 % Diluted EPS Continuing Operations $ (0.12) $ (2.47) $ (0.04) 95 % nm Diluted EPS Total $ (0.12) $ (2.47) $ (0.02) 95 % nm Non-GAAP Diluted EPS Continuing Operations $ 0.16 $ 0.05 $ 0.13 nm 25 % Adjusted EBITDA - C
BURLINGTON, Mass., July 24, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 7, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling im
4 - Azenta, Inc. (0000933974) (Issuer)
3 - Azenta, Inc. (0000933974) (Issuer)
4 - Azenta, Inc. (0000933974) (Issuer)
BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on November 13, 2024. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solu
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i
BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. In contrast, Azenta's test makes use of PacBio's Revio sequencer to obtain long and highly accurate HiFi sequencing reads to cover regions that are inaccessible by short reads. Performed w
8-K - Azenta, Inc. (0000933974) (Filer)
8-K - Azenta, Inc. (0000933974) (Filer)
10-Q - Azenta, Inc. (0000933974) (Filer)
Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00
B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously
Raymond James initiated coverage of Azenta with a rating of Mkt Perform
William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P
Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
Throughout the last three months, 5 analysts have evaluated Azenta (NASDAQ:AZTA), offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 In the assessment of 12-month price targets, analysts unveil insights for Azenta, presenting an average target of $64.2, a high estimate of $75.00, and a low estimate of $53.00. A decline of 3.46% from the pr
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $52 to $53.